367 related articles for article (PubMed ID: 17695508)
1. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727.
Ono K; Suzuki T; Miki Y; Taniyama Y; Nakamura Y; Noda Y; Watanabe M; Sasano H
Anticancer Res; 2007; 27(4B):2231-9. PubMed ID: 17695508
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.
Kidd M; Schally AV; Pfragner R; Malfertheiner MV; Modlin IM
Cancer; 2008 Mar; 112(6):1404-14. PubMed ID: 18224665
[TBL] [Abstract][Full Text] [Related]
4. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].
Hofsli E
Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977
[TBL] [Abstract][Full Text] [Related]
5. Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats.
Schmid HA; Silva AP
J Endocrinol Invest; 2005; 28(11 Suppl International):28-35. PubMed ID: 16625842
[TBL] [Abstract][Full Text] [Related]
6. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors.
Schmid HA; Schoeffter P
Neuroendocrinology; 2004; 80 Suppl 1():47-50. PubMed ID: 15477717
[TBL] [Abstract][Full Text] [Related]
7. Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.
Pivonello C; Rousaki P; Negri M; Sarnataro M; Napolitano M; Marino FZ; Patalano R; De Martino MC; Sciammarella C; Faggiano A; Rocco G; Franco R; Kaltsas GA; Colao A; Pivonello R
Endocrine; 2017 Jun; 56(3):603-620. PubMed ID: 27688013
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors.
Moreno A; Akcakanat A; Munsell MF; Soni A; Yao JC; Meric-Bernstam F
Endocr Relat Cancer; 2008 Mar; 15(1):257-66. PubMed ID: 18310292
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor subtypes mediate contractility on human colonic smooth muscle cells.
Corleto VD; Severi C; Romano G; Tattoli I; Weber HC; Stridsberg M; Rindi G; Campanini N; Tomassoni F; Pagotto U; Coy DH; Jensen RT; Delle Fave G
Neurogastroenterol Motil; 2006 Mar; 18(3):217-25. PubMed ID: 16487413
[TBL] [Abstract][Full Text] [Related]
10. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization.
Reubi JC; Schaer JC; Waser B; Mengod G
Cancer Res; 1994 Jul; 54(13):3455-9. PubMed ID: 8012966
[TBL] [Abstract][Full Text] [Related]
11. Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells.
Pasquali D; Rossi V; Conzo G; Pannone G; Bufo P; De Bellis A; Renzullo A; Bellastella G; Colao A; Vallone G; Bellastella A; Sinisi AA
J Mol Endocrinol; 2008 Jun; 40(6):263-71. PubMed ID: 18502819
[TBL] [Abstract][Full Text] [Related]
12. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.
Modlin IM; Pavel M; Kidd M; Gustafsson BI
Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies.
Lambertini C; Barzaghi-Rinaudo P; D'Amato L; Schulz S; Nuciforo P; Schmid HA
Regul Pept; 2013 Nov; 187():35-41. PubMed ID: 24188818
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of proliferation, VEGF secretion of human neuroendocrine tumor cell line NCI-H727 by an antagonist of growth hormone-releasing hormone (GH-RH) in vitro.
Sacewicz M; Lawnicka H; Siejka A; Stepień T; Krupiński R; Komorowski J; Stepień H
Cancer Lett; 2008 Sep; 268(1):120-8. PubMed ID: 18486324
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro.
Lesche S; Lehmann D; Nagel F; Schmid HA; Schulz S
J Clin Endocrinol Metab; 2009 Feb; 94(2):654-61. PubMed ID: 19001514
[TBL] [Abstract][Full Text] [Related]
16. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
17. Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.
Gilbert JA; Adhikari LJ; Lloyd RV; Rubin J; Haluska P; Carboni JM; Gottardis MM; Ames MM
Endocr Relat Cancer; 2010 Sep; 17(3):623-36. PubMed ID: 20385747
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors.
Janson ET
J Endocrinol Invest; 2005; 28(11 Suppl International):137-40. PubMed ID: 16625863
[TBL] [Abstract][Full Text] [Related]
19. Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5?
Pisarek H; Pawlikowski M; Kunert-Radek J; Winczyk K
Endokrynol Pol; 2010; 61(2):178-81. PubMed ID: 20464704
[TBL] [Abstract][Full Text] [Related]
20. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion.
Murray RD; Kim K; Ren SG; Lewis I; Weckbecker G; Bruns C; Melmed S
J Clin Endocrinol Metab; 2004 Jun; 89(6):3027-32. PubMed ID: 15181094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
